Gaia Pellegatta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7293351/publications.pdf

Version: 2024-02-01

1477746 1473754 10 195 9 6 citations h-index g-index papers 11 11 11 526 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. American Journal of Gastroenterology, 2016, 111, 70-77.	0.2	59
2	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Journal of Hepatology, 2020, 73, 593-602.	1.8	38
3	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. Scandinavian Journal of Gastroenterology, 2016, 51, 1081-1086.	0.6	36
4	Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterology, 2017, 63, 175-183.	0.3	30
5	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1333-1341.	1.5	17
6	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. Korean Journal of Family Medicine, 2020, 41, 250-255.	0.4	7
7	Positive PET in a Patient With Esophageal Leiomyoma. American Journal of Gastroenterology, 2016, 111, 767.	0.2	4
8	Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. Annals of Hepatology, 2018, 17, 1072-1077.	0.6	3
9	Complexity and diversity of gastroesophageal reflux disease phenotypes. Minerva Gastroenterology, 2017, 63, 198-204.	0.3	1
10	Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals. Annals of Hepatology, 2018, 17, 0-10.	0.6	O